AstraZeneca (LON:AZN) received a GBX 7,900 ($103.23) price objective from investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday, Borsen Zeitung reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 8.56% from the company’s previous close.
Other equities research analysts also recently issued reports about the company. Credit Suisse Group set a GBX 7,300 ($95.39) target price on AstraZeneca and gave the stock a “buy” rating in a research report on Friday, October 25th. Societe Generale restated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, September 10th. Goldman Sachs Group set a GBX 5,500 ($71.87) target price on AstraZeneca and gave the stock a “sell” rating in a research report on Wednesday, October 30th. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research report on Thursday. Finally, Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Friday. Three analysts have rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of GBX 7,465.67 ($97.55).
AZN traded down GBX 10 ($0.13) during trading on Friday, reaching GBX 7,277 ($95.09). The stock had a trading volume of 1,564,493 shares, compared to its average volume of 2,310,000. The firm has a market capitalization of $95.47 billion and a price-to-earnings ratio of 45.65. The company has a quick ratio of 0.70, a current ratio of 0.92 and a debt-to-equity ratio of 148.59. AstraZeneca has a 1-year low of GBX 5,312 ($69.41) and a 1-year high of GBX 8,227.88 ($107.51). The stock has a 50 day moving average of GBX 7,153.54 and a two-hundred day moving average of GBX 6,640.56.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: What is basic economics?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.